Recursion Rings the Nasdaq Stock Market Opening Bell

Executives from Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company, visit the Nasdaq MarketSite in Times Square on January 22 to ring the Nasdaq Opening Bell and celebrate the “Era of TechBio.” Today’s bell ringing comes on the heels of Recursion’s recent business combination with Exscientia, which closed in November 2024, bringing expanded partnerships and pipeline, including both first-in-class and best-in-class programs across oncology and rare disease, as well as other unmet needs. To mark the occasion, Co-Founder and CEO Chris Gibson, PhD, rings the opening bell and share the Company’s vision for the exciting future of TechBio – as fit-for-purpose biological data, AI modeling, precision chemical design, and supercomputing capabilities have been brought together to massively accelerate the discovery and development of transformative new medicines.